» Articles » PMID: 29492674

Urinary CD80: a Biomarker for a Favorable Response to Corticosteroids in Minimal Change Disease

Overview
Journal Pediatr Nephrol
Specialties Nephrology
Pediatrics
Date 2018 Mar 2
PMID 29492674
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

Minimal Change Disease (MCD) is the most common type of nephrotic syndrome in children. The etiology has remained unknown, although it is commonly thought to be due to an unknown circulating factor that triggers podocyte dysfunction. To date, several changes in podocytes have been reported in MCD, of which one is the expression of CD80, also known as B7.1, which is a costimulatory molecule that is normally expressed on antigen -presenting cells. Some studies suggest that subjects with steroid-sensitive MCD may express CD80 in their podocytes during relapse and that this expression is associated with high urinary levels of CD80. Indeed, subjects with MCD in remission, or subjects with other glomerular diseases, such as focal segmental glomerulosclerosis, have substantially lower levels of urinary CD80 excretion. A recent study has now reported that high levels of urinary CD80 may be a sensitive marker for steroid-sensitivity and that their presence is also associated with long-term preservation of renal function. Thus, urinary CD80 is emerging as a potential biomarker for steroid-responsiveness in children presenting with primary nephrotic syndrome.

Citing Articles

Minimal change nephrotic syndrome due to certolizumab pegol, an anti-tumor necrosis factor-alpha monoclonal antibody for treatment of rheumatoid arthritis.

Sugiyama M, Okuda S, Hirooka Y Rheumatol Adv Pract. 2022; 6(1):rkac012.

PMID: 35252744 PMC: 8892364. DOI: 10.1093/rap/rkac012.


Clinical significance of T lymphocyte subsets, immunoglobulin and complement expression in peripheral blood of children with steroid-dependent nephrotic syndrome/frequently relapsing nephrotic syndrome.

Chen S, Wang J, Liang S Am J Transl Res. 2021; 13(3):1890-1895.

PMID: 33841716 PMC: 8014369.


CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.

Teh Y, Lim S, Jusoh N, Osman K, Mualif S Biomed Res Int. 2021; 2021:6671552.

PMID: 33506028 PMC: 7806396. DOI: 10.1155/2021/6671552.

References
1.
Goldwich A, Burkard M, Olke M, Daniel C, Amann K, Hugo C . Podocytes are nonhematopoietic professional antigen-presenting cells. J Am Soc Nephrol. 2013; 24(6):906-16. PMC: 3665387. DOI: 10.1681/ASN.2012020133. View

2.
Shimada M, Ishimoto T, Lee P, Lanaspa M, Rivard C, Roncal-Jimenez C . Toll-like receptor 3 ligands induce CD80 expression in human podocytes via an NF-κB-dependent pathway. Nephrol Dial Transplant. 2011; 27(1):81-9. DOI: 10.1093/ndt/gfr271. View

3.
Fiorina P, Vergani A, Bassi R, Niewczas M, Altintas M, Pezzolesi M . Role of podocyte B7-1 in diabetic nephropathy. J Am Soc Nephrol. 2014; 25(7):1415-29. PMC: 4073425. DOI: 10.1681/ASN.2013050518. View

4.
Novelli R, Gagliardini E, Ruggiero B, Benigni A, Remuzzi G . Another Piece of the Puzzle of Podocyte B7-1 Expression: Lupus Nephritis. Nephron. 2016; 133(2):129-38. DOI: 10.1159/000446324. View

5.
Mishra O, Kumar R, Narayan G, Srivastava P, Abhinay A, Prasad R . Toll-like receptor 3 (TLR-3), TLR-4 and CD80 expression in peripheral blood mononuclear cells and urinary CD80 levels in children with idiopathic nephrotic syndrome. Pediatr Nephrol. 2017; 32(8):1355-1361. DOI: 10.1007/s00467-017-3613-8. View